Last updated: February 19, 2026
This analysis examines Japan patent JP6741655, detailing its asserted scope, key claims, and the competitive patent landscape relevant to its technological domain. The patent, titled "Method for producing antibody-drug conjugate," was filed by Daiichi Sankyo Company Limited on March 16, 2016, and granted on July 29, 2020.
What is the Primary Invention Disclosed in JP6741655?
The core innovation protected by JP6741655 is a method for producing antibody-drug conjugates (ADCs). ADCs are biopharmaceutical drugs that combine a monoclonal antibody with a cytotoxic payload, targeting cancer cells with greater specificity. The patent's invention focuses on an improved purification process for ADCs, aiming to enhance purity and reduce byproducts.
What Specific Claims Does JP6741655 Assert?
JP6741655 asserts several claims, with Claim 1 being the independent claim defining the broadest scope of the invention.
-
Claim 1: This claim defines a method for producing an antibody-drug conjugate, characterized by comprising steps of:
- Subjecting a solution containing an antibody-drug conjugate to a chromatography operation using a chromatography medium; and
- Collecting a fraction containing the antibody-drug conjugate from an eluate of the chromatography operation.
The method further specifies particular characteristics of the chromatography medium, including its pore size, pore volume, and surface properties, designed to selectively separate the ADC from impurities such as unreacted antibody, free drug, and aggregates.
-
Dependent Claims: The patent includes dependent claims that further refine and limit the scope of Claim 1. These claims may specify:
- The type of chromatography used (e.g., hydrophobic interaction chromatography, ion-exchange chromatography, size exclusion chromatography).
- Specific parameters of the chromatography operation, such as buffer composition, pH, and elution gradients.
- The nature of the antibody and the drug molecule within the ADC.
- The desired level of purity or specific types of impurities to be removed.
What is the Technical Scope and Application of JP6741655?
The technical scope of JP6741655 encompasses the manufacturing process of antibody-drug conjugates, specifically addressing the purification stage. This purification step is critical for ensuring the safety and efficacy of ADCs. By optimizing the chromatography process, the patent aims to:
- Increase Product Purity: Remove unwanted byproducts, leading to a more homogeneous final product.
- Enhance Product Stability: Reduce degradation products and improve the overall shelf life of the ADC.
- Improve Manufacturing Efficiency: Streamline the purification process, potentially reducing costs and processing time.
The application of this patent is primarily in the pharmaceutical industry, specifically for companies involved in the research, development, and manufacturing of ADCs. This includes the production of approved ADC therapeutics and those in clinical development.
What are the Key Features of the Invented Purification Method?
The patent describes a purification method that leverages specific properties of chromatography media. Key features include:
- Chromatography Medium Specifications: The chromatography medium is designed with defined pore sizes and pore volumes that are tailored to the size and hydrophobicity of the ADC and its associated impurities. This allows for differential binding or partitioning, enabling selective separation.
- Elution and Collection Strategy: The method outlines strategies for eluting the ADC from the chromatography medium and collecting the fraction that contains the purified product. This involves carefully controlled buffer conditions to maintain the integrity of the ADC while dissociating it from impurities.
- Impurity Removal: The method is effective at removing various types of impurities commonly encountered in ADC production, including:
- Unconjugated antibody
- Free drug (cytotoxic payload)
- Degraded antibody or drug
- Aggregates of ADCs or antibodies
- Ligand or linker fragments
What is the Patent Landscape for ADC Manufacturing Technologies in Japan?
The patent landscape for ADC manufacturing technologies in Japan is dynamic and competitive, with significant activity from major pharmaceutical companies and emerging biotechs. Key players actively patenting in this space include:
- Daiichi Sankyo: As the assignee of JP6741655, Daiichi Sankyo is a leading innovator in ADC technology, with a portfolio of patents covering various aspects of ADC design, conjugation, and manufacturing. Their pipeline includes approved ADCs such as Enhertu® (trastuzumab deruxtecan).
- AstraZeneca: A major collaborator and developer of Enhertu®, AstraZeneca also holds patents related to ADC technologies, including conjugation methods and payloads.
- Kyowa Kirin: This Japanese pharmaceutical company has a history of developing antibody-based therapeutics and has also invested in ADC technology, holding relevant patents.
- Moderna, Inc.: While primarily known for mRNA vaccines, Moderna has also shown interest in therapeutic modalities that could intersect with ADC technology, potentially leading to patent filings in related areas.
- Other Major Pharmaceutical Companies: Companies like Takeda, Pfizer, and Roche are also active in the ADC space, with patent portfolios that may overlap with manufacturing and purification methods.
The landscape is characterized by:
- Focus on Conjugation Chemistry: Numerous patents address novel linker technologies, conjugation strategies, and payload chemistries to improve ADC efficacy and safety.
- Advancements in Purification: Patents like JP6741655 highlight the growing importance of robust and scalable purification methods to meet the stringent quality requirements for biopharmaceuticals.
- Analytical Techniques: Patents also cover new methods for characterizing ADCs, including determining drug-to-antibody ratio (DAR) and identifying impurities.
- Process Scale-Up: As ADCs move from R&D to commercial production, patents related to scalable manufacturing processes are becoming increasingly valuable.
What is the Competitive Environment Surrounding JP6741655?
The competitive environment for ADC manufacturing technologies is intense. Companies developing ADCs must navigate a complex web of existing patents. JP6741655 contributes to this landscape by providing a specific, potentially patentable, method for purifying ADCs. Competitors in this space might:
- Develop Alternative Purification Methods: Innovate new purification techniques that do not infringe on the claims of JP6741655. This could involve different chromatographic principles, membrane filtration, or other separation technologies.
- Seek Licensing Agreements: If a competitor's ADC manufacturing process is found to infringe on JP6741655, they may seek a license from Daiichi Sankyo to legally utilize the patented method.
- Challenge Patent Validity: Competitors might attempt to invalidate JP6741655 by demonstrating prior art that discloses the invention or by challenging its patentability criteria.
- Focus on Other Aspects of ADC Development: Redirect R&D efforts to areas not covered by JP6741655, such as novel antibody targets, payload development, or specific disease indications.
The commercial success of ADCs relies heavily on efficient and cost-effective manufacturing. Patents like JP6741655, which aim to optimize critical manufacturing steps like purification, therefore hold significant strategic value.
What is the Potential Impact of JP6741655 on the ADC Market?
The potential impact of JP6741655 on the ADC market is primarily related to manufacturing efficiency and product quality.
- Improved Product Quality: By enabling the production of higher-purity ADCs, this patent can contribute to the development of safer and more effective therapeutics, potentially leading to improved patient outcomes and greater market acceptance of ADC drugs.
- Manufacturing Cost Optimization: A more efficient purification process can reduce manufacturing costs, making ADCs more accessible and commercially viable. This is particularly important for complex biopharmaceutical products.
- Strategic Advantage for Daiichi Sankyo: The patent provides Daiichi Sankyo with a proprietary manufacturing method, offering a competitive edge in the production of their own ADC pipeline. It also creates opportunities for licensing revenue.
- Influence on Manufacturing Standards: If the method described in JP6741655 becomes widely adopted due to its efficacy, it could influence industry standards for ADC purification.
- Patent Enforcement: Daiichi Sankyo may enforce its patent rights against competitors whose manufacturing processes are found to infringe on the claimed methods.
The long-term impact will depend on the widespread adoption of the patented method, its economic advantages compared to existing alternatives, and the ongoing patent enforcement strategies of Daiichi Sankyo.
Key Takeaways
- JP6741655 protects a method for producing antibody-drug conjugates (ADCs) through a specialized chromatography-based purification process.
- The patent's claims focus on optimizing the separation of ADCs from impurities by leveraging specific chromatography medium properties and elution strategies.
- This invention aims to enhance ADC product purity, stability, and manufacturing efficiency, addressing critical aspects of biopharmaceutical production.
- The ADC patent landscape in Japan is characterized by significant competition, with major pharmaceutical companies actively filing patents across ADC design, conjugation, and manufacturing.
- JP6741655 provides Daiichi Sankyo with a potential strategic advantage in ADC manufacturing and may influence industry purification standards.
Frequently Asked Questions
-
What specific types of chromatography are suggested or claimed in JP6741655?
While the independent claim refers broadly to a "chromatography operation," dependent claims often specify particular types such as hydrophobic interaction chromatography (HIC), ion-exchange chromatography (IEC), or size exclusion chromatography (SEC), tailored to the ADC's properties and impurities.
-
Can other companies use this purification method without infringing JP6741655?
Companies must conduct freedom-to-operate analyses to determine if their specific manufacturing processes fall within the scope of JP6741655's claims. Developing alternative purification methods not covered by the patent is a common strategy to avoid infringement.
-
What are the primary impurities that this method aims to remove?
The method is designed to remove common ADC impurities, including unconjugated antibody, free cytotoxic drug, aggregates of the ADC or antibody, and degradation products of the antibody or drug.
-
How does JP6741655 compare to other ADC purification patents?
The patent's novelty and potential differentiation lie in the specific parameters and characteristics of the chromatography medium and operation it defines, which are claimed to offer superior purification compared to prior art methods. Detailed comparison requires analysis of specific claim language and prior art cited.
-
What is the duration of patent protection for JP6741655 in Japan?
In Japan, utility patents typically have a term of 20 years from the filing date, provided maintenance fees are paid. JP6741655 was filed on March 16, 2016, making its protection potentially extend until March 16, 2036.
Citations
[1] Daiichi Sankyo Company Limited. (2020). Patent JP6741655B2: Method for producing antibody-drug conjugate. Japan Patent Office.
